📇 Rhumatologue · PARIS CEDEX 05 · (75) · Salarié

MME LIVIA LUMBROSO-LE ROUIC

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
23 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS CEDEX 05 (75)SalariéRPPS 10001411296

📊 Reconnaissance scientifique : 33/100📝 143 articles publiés🇫🇷 Publications académiques françaises (7)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma

The British journal of ophthalmology · 2014

📚 95 citations🎯 RCR 3.31Top 14% NIH🔓 Open Access📄 PDF gratuit ↗

Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma

Pediatric blood & cancer · 2009

📚 81 citations🎯 RCR 2.86Top 17% NIH

Lire l'abstract Crossref ↓

AbstractBackgroundCarboplatin plays an important role in the conservative management of retinoblastoma, but is associated with risk of ototoxicity in these young children whose sensory prognosis may be also compromised by their loss of vision. This retrospective study analyzed the impact of carboplatin on hearing in the context of conservative management of children with retinoblastoma.MethodsData for 175 children treated at the Institut Curie between 1994 and 2002 were analyzed.ResultsMedian age at diagnosis was 8 months (0–60). Carboplatin was administered on 3 days (200 mg/m2/day) or 5 days (160 mg/m2/day) with etoposide and with diode‐laser therapy at the dose of 560 mg/m2 (chemothermotherapy). Median cumulative dose of carboplatin was 2,880 mg/m2 (560–6,160). Ototoxicity was investigated by pure‐tone audiometry and scored by Brock's grading scale before and after treatment. The median follow‐up of hearing assessment was 5 years (1.8–11). Ototoxicity was detected in 8 children: 3 grade 1, 1 grade 2, and 2 grade 4. The two patients with grade 4 hearing‐loss required a hearing aid. Two children developed bilateral high frequency hearing‐loss, considered to be secondary to carboplatin but with less than Brock grade 1. Ototoxicity was observed for a median cumulative dose of carboplatin of 3,120 mg/m2 (1,200–5,830). Only one child developed ototoxicity during treatment. All other cases were discovered after the last dose of carboplatin with a median interval of 3.7 years (0–7.6). No other risk factor for ototoxicity was able to account for these lesions.ConclusionChildren receiving carboplatin require long‐term audiometric follow‐up. Pediatr Blood Cancer 2009;52:637–643. © 2009 Wiley‐Liss, Inc.

Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison

Pediatric radiology · 2007

📚 66 citations🎯 RCR 2.57Top 20% NIH

Cookies & analyse de trafic

MME LIVIA LUMBROSO-LE ROUIC

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (23) — classées par pathologie

Transversal10

Pédiatrie6

Génétique4

Essai clinique1

Pharmacovigilance1

Revue / méta-analyse1

Revue générale1

Santé mentale / fatigue1

Vraie vie / RWE1

Partager cette fiche